1. |
趙鐵軍,田伏洲,尹志良,等.新城疫病毒治療肝癌10例 [J].世界華人消化雜志,1999; 7(6)∶ 718.
|
2. |
Schirrmacher V, Haas C, Bonifer R, et al. Viros potentiation of tumor vaccine Tcell stimulatory capacity requires cell surface binding but not infection [J]. Clin Cancer Res, 1997; 3(7)∶1135.
|
3. |
Haas C, Ertel C, Gerhards R, et al. Introduction of adhesive and costimulatory immune functions into tumor cells by infection with Newcastle Disease Virus [J]. Int J Oncol,1998; 13(6)∶1105.
|
4. |
Kenney S,Pagano JS. Viruses as oncolytic agents: a new age for “therapeutic” viruses? [J]. J Natl Cancer Inst, 1994; 86(16)∶1185.
|
5. |
Yeow WS, Beilharz MW,Lai CM. The in vitro expression patterns of individual type I interferon genes in Newcastle disease virus infected murine splenocytes and fibroblasts [J]. Int J Biochem Cell Biol,1997; 29(3)∶513.
|
6. |
Weidmann E, Trucco M, Whiteside TL. Relevance of the T cell receptor for immunotherapy of cancer [J]. Cancer Immunol Immunother, 1994; 39(1)∶1.
|
7. |
Kagi D, Seiler P, Pavlovic J, et al. The roles of perforin and Fasdependent cytotoxicity in protection against cytopathic and noncytopathic viruses [J]. Eur J Immunol, 1995; 25(10)∶3256.
|
8. |
Bradley LM, Yoshimoto K,Swain SL. The cytokines IL4, IFNgamma, and IL12 regulate the development of subsets of memory effector helper T cells in vitro [J]. J Immunol, 1995; 155(4)∶1713.
|
9. |
Noble A, Macary PA,Kemeny DM. IFNgamma and IL4 regulate the growth and differentiation of CD8+ T cells into subpopulations with distinct cytokine profiles [J]. J Immunol, 1995; 155(6)∶2928.
|